Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RGT 61159

Drug Profile

RGT 61159

Alternative Names: RGT-61159

Latest Information Update: 16 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rgenta Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c-myb expression inhibitors; RNA splicing modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Adenoid cystic carcinoma; Colorectal cancer
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 16 Jul 2024 Phase-I clinical trials in Adenoid cystic carcinoma (Metastatic disease, Second-line therapy or greater) in USA (PO), prior to July 2024 (NCT06462183)
  • 16 Jul 2024 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (PO), prior to July 2024 (NCT06462183)
  • 11 Jul 2024 Rgenta Therapeutics announces the clearance of IND application for RGT 61159 by the US FDA for the treatment of Adenoid cystic carcinoma and Colorectal cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top